NVision announced a $55 million Series B financing round as the company expands from quantum sensing into quantum computing, with the goal of accelerating the discovery and validation of new therapies. The funding round was anchored by Abbott and also included a $17 million venture loan from the European Investment Bank. Other investors participating in the round included Playground Global, Matterwave Ventures, and Entrée Capital. The new financing brings NVision’s total capital raised to $120 million. NVision’s quantum-enhanced sensing platform, POLARIS, leverages quantum technology to amplify MRI signals from sugar-based imaging agents, enabling real-time metabolic measurements with standard MRI systems. The platform is designed to help researchers assess treatment response within hours or days based on disease biology rather than waiting months for conventional imaging methods to reveal morphological changes. The company is now extending the molecular quantum approach behind POLARIS into quantum computing. During the development of its MRI signal enhancement technology, NVision discovered a new class of organic molecule-based qubits. The company believes these qubits can support a new quantum-driven approach to drug development by enabling the design of more effective drug candidates while POLARIS rapidly validates them in biological environments. NVision’s vision is to create a unified “compute and validate” system that combines quantum computing for drug design with quantum sensing for real-world therapeutic validation. POLARIS systems are already being installed at leading cancer centers around the world, with deployments expected at approximately 20 centers across the U.S., Europe, and Asia by the end of the year. Sites include Memorial Sloan Kettering Cancer Center, University of Cambridge, and Technical University of Munich. The company also introduced its quantum computing platform known as Photonic Integrated Quantum Circuits, or PIQC, pronounced “Pixie.” The platform uses single photon-emitting organic molecules integrated as thin organic layers onto photonic chips, creating a